Here, we investigated the role of the miR-22/GLUT1 axis in hepatocarcinogenesis, glycolytic shift, and sorafenib resistance, and evaluated miR-22 as a circulating biomarker of sorafenib response in HCC. Here, SLC2A1 is linked to hepatocellular carcinoma.